Published in final edited form as:

Alzheimer Dis Assoc Disord. 2008 ; 22(1): 6–20. doi:10.1097/WAD.0b013e31816653ac.

Children of Persons With Alzheimer Disease:

What Does the Future Hold?

Lissy Jarvik, MD, PhD^{*,†,‡}, Asenath LaRue, PhD[§], Deborah Blacker, MD, ScD^{||}, Margaret Gatz, PhD[¶], Claudia Kawas, MD[#], John J. McArdle, PhD[¶], John C. Morris, MD^{**}, James A. Mortimer, PhD^{††}, John M. Ringman, MD^{‡‡}, Linda Ercoli, PhD^{*,‡}, Nelson Freimer, MD^{*,‡}, Izabella Gokhman, MD^{§§}, Jennifer J. Manly, PhD^{||,|||}, Brenda L. Plassman, PhD^{¶¶}, Natalie Rasgon, MD, PhD^{##}, Jeffrey Scott Roberts, PhD^{***}, Trey Sunderland, MD^{†††}, Gary E. Swan, PhD^{†††}, Phillip A. Wolf, MD^{§§§}, and Alan B. Zonderman, PhD^{||,|||}

^{*}Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA

^{‡‡}Department of Neurology and Alzheimer's Disease Research Center, University of California, Los Angeles, CA

[†]Department of Veterans Affairs, VA Greater Los Angeles Health Care System, Los Angeles, CA

[‡]Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA

[¶]Department of Psychology, University of Southern California, Los Angeles, CA

[#]Departments of Neurology and Neurobiology and Behavior, University of California, Irvine, CA

^{§§}South Bay Mental Health Center, Los Angeles County, Department of Mental Health, Hawthorne, CA

^{##}Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA

^{†††}Center for Health Sciences, SRI International, Menlo Park, CA

[§]Department of Medicine, Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, WI

^{||}Massachusetts General Hospital, Harvard Medical School, Boston, MA

^{§§§}Framingham Heart Study, Boston University School of Medicine, Boston, MA

^{**}Washington University School of Medicine, St. Louis, MO

^{††}Department of Epidemiology and Biostatistics, College of Public Health, MDC-University of South Florida, Tampa, FL

^{|||}GH Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY

^{¶¶}Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC

^{***}Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI

^{†††}Chevy Chase, Intramural Research Program, Baltimore, MD

^{|||}National Institute on Aging, Intramural Research Program, Baltimore, MD

Abstract

Children of persons with Alzheimer disease (AD), as a group, face an increased risk of developing AD. Many of them, throughout their adult lives, seek input on how to reduce their chances of one day suffering their parent's fate. We examine the state of knowledge with respect to risk and protective factors for AD and recommend a research agenda with special emphasis on AD offspring.

Keywords

Alzheimer disease offspring; risk factors

Much has been learned about Alzheimer disease (AD) since Alois Alzheimer first described it more than a century ago,¹ but to date no consensus has been reached on its etiology, no universally accepted preventive interventions have become available, and treatments are only minimally effective. Although a considerable amount of research is underway, much of it is as yet inconclusive and often mired in significant methodologic challenges. Meanwhile, the number of persons afflicted with AD has been steadily increasing. For the United States alone, estimates have been as high as 5 million in 2007,² up from 4 million.³ Others, using different diagnostic criteria, estimated the prevalence of AD at 1.9 million.^{4,5} The most recent report, the Aging Demographic and Memory Study (ADAMS),⁶ a supplemental study of the Health and Retirement Study, yielded an estimate of 2.5 million individuals with AD at the age of 60 years and older in the United States in 2002. ADAMS was based on a nationally representative population sample with in-person assessments of 856 individuals between 2001 and 2003. It is the first study to assess individuals from all regions of the United States to estimate prevalence of dementia and, therefore, should account for regional and ethnic differences in prevalence. Whatever their precise numbers, AD patients are expected to increase as the estimated 70 to 80 million baby boomers (with their advancing age and increasingly greater longevity compared with prior more vulnerable to manifesting the disease. For example, by 2050, the number of people with AD in the United States may range from 11 to 16 million.²

Concerning global prevalence, the best estimates available suggest that 24 to 27 million individuals currently have AD and this number is projected to rise to more than 100 million by 2050.^{7,8} However, the rate of increase over that interval is not expected to be uniform. Differences in life expectancy across regions of the world, differences in survival after diagnosis of dementia, varying diagnostic conventions, and difficulties in ascertainment (especially in residents of rural underdeveloped areas) and differential exposure to risk factors may play a role (eg, low levels of cardiovascular risk found in some developing countries). Some investigators concluded that incidence and prevalence of dementia show relatively little geographical variation once methodologic issues are taken into account, although there may be greater inconsistencies in some types of dementia (eg, AD) than in others.⁹ Much more information than currently available is clearly needed.

In light of the increasing magnitude of the suffering caused by AD, and considering its economic burden (in the United States more than \$148 billion/y in 2007²), the search for factors that might increase or lower the risk of manifesting the disease takes on crucial importance. Observational studies have already suggested several factors that might trigger, induce, or accelerate the development of AD; yet, only a few are generally accepted.^{10,11} Although it may take many years before efforts to prevent or successfully treat AD will come to fruition, even delaying its onset could substantially reduce prevalence and cost.^{12,13}

Further research may be of particular urgency for the population of adult children of persons with AD (“AD offspring”) as they themselves advance in age. There are, however, surprisingly few data available on the risks faced specifically by AD offspring.¹⁴ Even their overall number, which most likely ranges well into millions, remains as yet unknown. Longitudinal studies ongoing worldwide are expected to yield much needed information. In the United States, for example, studies focusing on AD offspring include, but are not limited to, the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study,¹⁵ the Wisconsin Registry for Alzheimer Prevention (WRAP) study,¹⁶ the Washington University Adult Children study,¹² and the Framingham Offspring study.¹⁷ Results of these investigations will complement what has been learned from longitudinal studies of mixed samples of AD relatives (children and siblings or parents), including the National Institute of Mental Health’s Biomarkers in Older Controls At Risk for Dementia (BIOCARD) study,¹⁸ studies of persons at risk for AD,^{19–26} additional family studies of AD,^{27–31} and twin studies.³²

In this article, we will (i) briefly summarize generally accepted information regarding risk and protective factors and (ii) make recommendations for a research agenda designed to assess genetic and nongenetic risks and protective factors with special emphasis on AD offspring. Our purpose is not to supply a comprehensive review of the literature, but to provide enough background to understand the urgent need for further research in AD and the recommendation of strategies for future research.

RISK FACTORS FOR AD

Risk factors for AD are notoriously difficult to isolate as they interact with each other in a variety of ways. As a result, the outcomes of different studies are sometimes hard to reconcile and frequently require further clarification. Moreover, there is no uniform method of reporting (eg, prevalence, incidence, and lifetime risk), further complicating comparison of study outcomes. Nevertheless, 2 risk factors have become firmly established: chronologic age and positive family history.

Chronologic age has emerged as a crucially important risk factor, not only in itself but also, as we will see, through its interactions with a variety of other risk factors. For example, in a recent collaborative study carried out in 8 European countries, the pooled AD incidence rate per 1000 person-years rose from 1.2 to 9.1 and 35.3 for ages 65 to 69, 75 to 79, and 85 to 89 years, respectively.³³ In the United States, the current prevalence of AD is estimated as 2%, 19%, and 42% for age groups 65 to 74, 75 to 84, and 85+ years, respectively.²

Positive family history of AD is another risk factor for AD, independent of any identified genetic factors. It is generally reported that a person with at least 1 first-degree relative with dementia has 2 to 4 times the lifetime risk of developing AD compared with someone without such a relative.²⁸ These estimates may be sensitive to age structure and other modeling issues, such as the uncertainty of the diagnosis of AD/dementia in long-deceased relatives, and conversely, the inability to classify relatives who did not live through the age of risk as clearly free of AD/dementia. Moreover, although positive family history increases the risk for developing AD, this effect may diminish with age and may be minimal or absent after the age of 85 years.³¹ Other studies point to a different interaction effect of chronologic age and positive family history. The age at which the first-degree relative with AD (proband) manifests the symptoms of AD [age at onset (AAO)] may itself be a risk factor for the development of AD. The younger the proband’s AAO, the greater the genetic risk for the relatives, regardless of the age of the relatives themselves.^{34,35}

Within the group of first-degree relatives, the highest risk is faced by persons who have an identical twin with AD. The study of twins (identical or monozygotic and fraternal or

dizygotic) offers a unique opportunity to explore the relative contributions of genetic and other influences to the risk of developing AD. In the largest twin study to date, the Swedish twin study,³² heritability of AD was estimated to be 58%, with nongenetic risk factors playing an important role (nonshared environmental influences 23%, shared environmental influences 19%). In addition, twin studies clearly document that even in concordant twins (ie, both twins develop AD) there can be differences in AAO of as much as 16 years, indicating that the effects of both chronologic age and positive family history vary significantly as they interact with other risk factors.

Genetic Risk Factors

AD provides one of the best examples of the importance of distinguishing between 2 types of genetic variants that contribute to the risk of developing a disease: (i) Highly penetrant variants are usually rare, inherited in a simple (Mendelian) pattern, and provide remarkable insight into the basic biologic process underlying the disease. (ii) Less penetrant variants display complex segregation patterns and, therefore, may be less informative than Mendelian variants with respect to elucidation of pathobiology. However, they are often common, which increases the likelihood that they will substantially enhance our understanding of disease risk at the population level.³⁶ More than 100 genes have been implicated in the development of AD through genetic association studies (see AlzGene, www.alzgene.org³⁷) and other studies,^{38–43} but only 4 genes have so far been clearly established as contributing to the development of the disease: the 3 so-called “Alzheimer genes” [Amyloid Precursor Protein (*APP*), *Presenilin 1* (*PS1*), and *Presenilin 2* (*PS2*)] and the susceptibility gene *APOEε4*. The 3 Alzheimer genes all display rare but highly penetrant autosomal dominant mutations that lead to early-onset AD. In the 1980s, the study of the Alzheimer plaques, consisting largely of β -amyloid protein ($A\beta$), focused interest on $A\beta$ ⁴⁴ and led to the discovery that alterations in *APP* on chromosome 21 are a cause of some cases of familial AD.⁴⁵ *PS1*⁴⁶ and *PS2*⁴⁷ were subsequently discovered by linkage to other families with AD. The pathogenic mutations in all 3 of these genes were found to have the common effect of causing aberrant processing of APP to produce elevated levels of $A\beta_{42}$,⁴⁸ the more fibrillogenic form of $A\beta$ thought to be the most critical in causing the amyloid pathology. Further evidence for this “amyloid hypothesis” came from the study of Down syndrome with essentially all persons living into their sixth decade of life developing AD neuropathology and some progressive cognitive and behavioral deterioration.⁴⁹ The amyloid hypothesis unifies a number of diverse observations, contributes substantially to our understanding of the pathobiology of AD,^{21,50,51} and has opened up promising therapeutic avenues even though overproduction of $A\beta_{42}$ does not by itself explain all aspects of AD pathology.⁵² However, the Alzheimer genes are so rare that all 3 account for <1% of AD.⁵¹

By contrast, the $\epsilon 4$ allele of the gene encoding apolipoprotein E (*APOE ε4*) has been established as the most important genetic risk variant in population samples of all ages. *APOE ε4* is common but only modestly penetrant, and it remains unclear at a biologic level as to how it contributes to the development of AD. Diverse animal experiments have suggested that the risk of *APOE ε4* for AD may be mediated through either amyloid-dependent⁵³ or amyloid-independent⁵⁴ pathways. We expect that multiple additional AD susceptibility genes (most likely relatively low penetrance variants) and nongenetic risk factors will be discovered that contribute to AD risk. Fortunately, the technology is now available to identify such variants through well-powered genome-wide association (GWA) studies. The International HapMap Project⁵⁵ has identified several million single nucleotide polymorphisms (SNPs) that can be used (employing currently available commercial assays) to conduct GWA studies in samples drawn from diverse ethnic populations. Some GWA studies of AD are now underway. The cost is relatively low even for samples of several thousand individuals.

APOE ε4, the only confirmed susceptibility gene for AD, has been found in over 100 studies to increase vulnerability to AD at all ages. In the United States, about one-half to two-thirds of persons with late-onset AD carry the *APOE* ε4 allele.^{56–58} The frequency varies with age and findings vary as to the magnitude of risk conferred by *APOE* status.⁵⁹ A recent analysis of European Americans⁶⁰ determined that ε4 homozygotes occurred significantly more often among individuals with early-onset AD (20.3%) than among late-onset AD (8.2%) confirming the findings from previous studies. It has been known for a decade⁶¹ that the *APOE* ε4 effect is evident at all ages between 40 and 90 years, but diminishes after the age of 70 years. For heterozygous *APOE* ε4 carriers, compared with noncarriers, the increased lifetime risk of developing AD has been estimated as 3-fold to 4-fold, and for homozygotes as 2-fold to 10-fold or 15-fold. In population studies, the percentage of persons with AD carrying 1 or 2 *APOE* ε4 alleles ranges from approximately 50% to 70%.⁵⁶ Risk estimates for dementia in the general population range from 25% to 50%, and studies of *APOE* ε4 homozygotes found a dementia prevalence of 50%⁶² or less.^{57,61}

Global variation in *APOE* ε4 allelic frequency could contribute to different rates of AD among populations with European, Asian, and African ancestry. In European populations, prevalence estimates for the *APOE* ε4 allele range from 7.3% (Poles) to 19.8% (Norwegian); the range is somewhat more restricted in Asia/East Asia, extending from 0.0% (Koch) to 17.0% (Javanese), and wider in Africa, where prevalence estimates range from 3.0% (Senegal) to 40.7% (Biaka). Allele frequencies are available at <http://alfred.med.yale.edu>. An extensive review of ethnic differences⁶³ concludes that despite differences in sampling methods, definitions of dementia, and definitions of race/ethnicity as well as discrepancies in functional and neuropsychologic assessments, there are ethnic differences in the observed prevalence and incidence of cognitive impairment, dementia, and AD. Although AD has been found in all ethnic groups that have been examined, data are relatively scarce, and arguably might be more indicative of the challenges of culturally fair measurement than of decreased cognitive functioning in the test subjects.^{64–66} For example, despite its relatively low frequency in China (8.1%), the *APOE* ε4 allele remains an important risk factor for AD.⁶⁷ Indeed, according to more recent epidemiologic studies, the rate of AD in China may be similar to that in western populations.⁶⁸ It is possible also that *APOE* ε4 may not function as a risk factor across all populations such as in Chinese of Guangzhou⁶⁹ and Nigerians of Ibadan.⁷⁰ In African Americans too, several studies show little to no increase in the risk of AD with the *APOE* ε4 allele,^{61,71–73} whereas others did find an association between *APOE* ε4 and AD.^{74–76} The Wadi-Ara Arabs in northern Israel constitute another population of interest, given their unusually low ε4 allele frequency despite high rates of AD.⁷⁷ According to 1 report,⁷⁸ lower serum cholesterol was related to reduced risk of AD only in those who carried no ε4 alleles. Overall, the global data currently available do not support definitive conclusions regarding *APOE* ε4 and AD (small sample sizes and widely differing methods across studies may be among the most important reasons). Nonetheless, *APOE* has been considered a good “anthropogenetic and clinical diagnostic marker.”⁷⁹

It is important to remain aware of the fact that not all carriers of the ε4 allele develop AD, even if they live to advanced old age, and many without ε4 do manifest the disease.^{57,61,62,80–83} A variety of interacting risk and protective factors (as discussed below) has been implicated, but the mechanisms of these interactions are as yet to be explored. Meanwhile, the value of *APOE* in the diagnosis of AD remains to be established. *APOE* status has explicitly *not* been recommended for prediction by multiple national panels⁸⁴ (see <http://www.acmg.net/resources.policies/pol-001.asp> for the American College of Medical Genetics consensus statement recommending against routine genotyping of *APOE*).

Prominent among ongoing research exploring *APOE*-related issues is the multicenter REVEAL study,¹⁵ aimed at understanding the impact of *APOE* testing. Careful estimates of the relation between *APOE*, positive family history, and disease risk, prepared for this study⁸⁵ suggest that the risk was highest for persons with 1 or more *APOE* $\epsilon 4$ alleles and a first-degree relative with AD. As mentioned earlier, however, the effect of positive family history varies with age until a maximum age after which it may no longer make a significant difference. *APOE* status may interact with chronologic age in a similar pattern: A recent update on dementia⁵¹ confirmed earlier reports^{61,86} that the *APOE* $\epsilon 4$ effect is strongest before the age of 75 years. Among findings supporting this conclusion are those of the Cache County study,^{87,88} which indicate that the age-specific prevalence of AD reaches a maximum and then declines. The maximum was reached at the average ages of 73 and 87 years in *APOE* $\epsilon 4$ homozygotes and heterozygotes, respectively, whereas the comparable age in participants without $\epsilon 4$ alleles was 95 years. It has, therefore, been suggested that the strongest influence of *APOE* $\epsilon 4$ may be in accelerating the AAO of AD, and thereby, also lowering the age of maximum risk.⁸⁷

In a similar vein, it has been proposed that *APOE* $\epsilon 4$ may be an indicator of a general frailty factor that may lead to death before the AAO of AD.^{89,90} At the same time, this general frailty factor may increase vulnerability to AD in those who live long enough to manifest the disease. *APOE* $\epsilon 4$ has also been implicated in the excess mortality associated with AD, but again, the mechanisms behind this risk have as yet not been identified.⁹¹ Methodologic issues have hampered research in this area and further investigations will require sophisticated methodology such as multistage survival models.

APP, *PS1*, *PS2*, and *APOE* $\epsilon 4$ overall account but for a small amount of the genetic component of the risk of AD. Additional unidentified genes are clearly in operation. As mentioned before, over 100 genes have already been implicated but have not as yet been confirmed. One recent example is the proposed linkage of AD risk to variants in the intronic region of the *SORL1* neuronal sorting receptor.⁹² These variants may regulate the expression of *SORL1* that is involved in directing the intracellular trafficking of APP. Differences in *SORL1* expression levels could lead to quantitative differences in the pathways through which APP is processed. A second example comes from a recent genome-wide survey reporting that polymorphisms in the gene encoding for growth factor receptor-bound-associated binding protein-2 (GAB2) were associated with an increased risk of AD among persons carrying the *APOE* $\epsilon 4$ allele.⁹³

Other Risk Factors

In addition to age, positive family history, the 3 Alzheimer genes, and *APOE* $\epsilon 4$, other potential risk factors such as head trauma, cardiovascular disease, hypertension, diabetes, and atherosclerosis have been suggested.¹² Sex (even after accounting for survival differences) may interact with *APOE* $\epsilon 4$ to influence cognitive decline^{57,88,94} and, so may educational attainment and brain reserve.^{95,96} The association between smoking and the development of dementia is unclear. Although animal experiments generally show a detrimental effect,⁹⁷ results of epidemiologic studies have varied, the more recent ones tending to show an increased risk for dementia in long-term smokers.⁹⁸

There has also been support from epidemiologic studies for the protective effect of nutrition and dietary supplements.^{99,100} Reportedly, certain fish,¹⁰¹ n-3 fatty acids,¹⁰¹ antioxidant supplements,^{102–104} homocysteine,¹⁰⁵ and reduction of intake of saturated and trans-unsaturated fat¹⁰⁶ may provide protection against AD. There is some evidence that these dietary factors may interact with the *APOE* $\epsilon 4$ allele, but not in a consistent fashion.¹⁰⁷ In addition to, and possibly interacting with diet, exercise has been suggested as a potential protective factor. An emerging body of literature supports that suggestion, concluding that

physical exercise may protect against dementia.¹⁰⁸ Some of the positive effects of exercise likely reflect its effect on preserving cardiovascular health. Additionally, exercise has been shown to lead to increases in brain-derived neurotrophic factor (BDNF) that would promote brain plasticity.¹⁰⁹

Other research has suggested that cognitively stimulating activity in mid-life and late-life may delay or prevent AD.^{110–112} Finally, there is some evidence that occupations with higher cognitive demands may protect against manifestation of AD.^{113,114} Notably, studies of leisure activities and occupation are observational and can suffer from reverse causation and third-variable problems that cannot be entirely answered by adding covariates to the analyses. Nonetheless, nutrition and daily activities are to a certain extent under an individual's control. In this sense, they are potentially modifiable by the individual and thus have appeal as targets for interventions.

Depression has long been associated with AD (as a precursor, prodrome, and symptom); yet, the links between them remain to be clarified. Nearly a decade ago, a relationship was reported between insulin levels and severity of AD and *APOE* genotype,¹¹⁵ and more recently, a hypothesis proposed that insulin resistance (IR) may link AD and depression.¹¹⁶ Epidemiologic evidence supports an association between insulin dysregulation, cognitive decline, and AD.¹¹⁷ Although the exact mechanism of action of IR in the central nervous system is not known, it is thought that IR may lead to inadequate brain glucose metabolism. Glucose dysregulation clearly seems to increase the risk of AD even after exclusion of cardiovascular risk factors¹¹⁸; moreover, an association between IR-related vascular disorders and AD has been documented.¹¹⁹ It has also been pointed out that IR may develop as a consequence of weight gain and obesity associated with the neurovegetative symptoms of depression and some of the common pharmacologic treatments for depressive disorders such as use of atypical antipsychotics and anticonvulsants.¹²⁰

Diabetes has been reported to increase risk for cognitive decline and AD.^{117,121–126} Potential mechanisms for an association between diabetes and AD are (a) through cerebrovascular disease,¹²⁷ (b) through increased oxidative stress,¹²⁸ (c) through generation of advanced glycosylated end products,¹²⁹ and (d) through insulin.¹³⁰ The Washington Heights/Hamilton Heights/Inwood Columbia Aging Project (WHICAP)¹³¹ and Rotterdam¹²⁴ studies reported an increased association between diabetes and AD in subjects treated with insulin and a large proportion of diabetes in the elderly may be explained by IR.¹²⁸

In addition to the likelihood that the IR-depression–AD association will help to identify biologic mechanisms in the development of AD, it has potential clinical usefulness. Early identification of a subgroup of patients with depressive disorders and IR, with or without additional risk factors for AD, could lead to appropriate changes in medication regimens, preventive measures targeting AD, earlier diagnosis, and intervention.

Observational data have suggested an association between hyperlipidemia and AD,^{132,133} and also an association between use of lipid-lowering medications,¹³⁴ and a decreased risk of AD. In an observational study of 1037 postmenopausal women with coronary heart disease enrolled in the Heart and Estrogen/Progestin Replacement Study, women in the highest low-density lipoprotein (LDL) cholesterol quartile at cognitive testing had low Modified Mini-Mental State Examination scores and an increased likelihood of cognitive impairment.¹³⁵ However, other studies^{136,137} failed to find the association.

Risks Faced by AD Offspring

We have not been able to find specific risk estimates for AD offspring in our survey of the literature.¹⁴ One of the few studies focusing on AD offspring is the previously cited and ongoing multisite REVEAL study. In a series of randomized clinical trials of the predictive use of *APOE* testing, AD offspring and siblings have been provided risk information that incorporates *APOE* test results, and the psychologic and behavioral impact of this risk information on participants has been assessed up to 1 year after disclosure.¹⁵ Results to date suggest that genetic risk information for AD, when delivered in a controlled research context by trained professionals, does not generally result in adverse psychologic effects among recipients. The study uses risk curves to clarify to participants the meaning of their *APOE* results.⁸⁵ In the absence of data specific for AD offspring, the risk curve estimates are based on family history data from other populations, such as the multicenter Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) study of nearly 13,000 siblings and parents of AD patients and a 50-study pooled analysis of *APOE*-AD association in general populations. At this stage, like many other studies, REVEAL has no choice but to combine the risks for different types of first-degree relatives. However, discrepancies in frequencies obtained for parental as compared to sibling dementia, suggest that although it may be appropriate to use combined risk estimates for first-degree relatives when estimating purely genetic risks for developing AD, it may be suboptimal to do so when estimating the overall risk faced by AD offspring.

Today, AD offspring have unprecedented opportunities to apply potentially protective measures against AD. The recent decrease in heart disease and stroke, which may lead to a potential reduction in risk for AD, may be attributable at least in part to the availability of such new information. Putative protective measures against AD include improved diet and lifestyle, increased exercise, mental stimulation, social interaction, and the consumption of vitamins, nutraceuticals, and over-the-counter as well as prescription drugs (such as hormones, statins, and anti-inflammatory agents). Moreover, educational attainment, which seems to decrease risk of AD, has increased markedly over the last 2 generations. However, there are also risk factors that are on the rise. For example, the emerging epidemic of obesity may lead to increased risk of AD¹³⁸ and the consequences of the widespread substance abuse, beginning in the 1960s, remain unknown.

The genetic risk to AD offspring may thus be strongly modified by nongenetic factors that influence the timing of onset and ultimate expression of AD. Whether a factor will affect risk for AD may depend on the timing and duration of the exposure before onset of clinical symptoms. Because individuals genetically vulnerable to AD may not react in the same way as the general population in whom the risk and protective factors were identified, studies of risk and protective factors specifically within groups of AD offspring are urgently needed. In this context, it is important to point out that most of what is known about nongenetic risk and protective factors for AD has been obtained from studies in which the family history of participants is either unknown or poorly documented. As a result, potential interactions of familial status with other risk and protective factors have not been adequately examined.

In contrast to the general lack of data on protective factors in AD offspring, 2 prevention trials targeted first-degree relatives of AD patients: the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) and the Preventing Postmenopausal memory loss and Alzheimer's with Replacement Estrogens (PREPARE) trial (see <http://clinicaltrials.gov> for study descriptions). An early report failed to detect significant differences in the ADAPT study.¹³⁹ Unfortunately, both trials were discontinued prematurely owing to concerns about drug safety (celecoxib and estrogen, respectively).

EARLY MARKERS

While awaiting clarification of interacting risk and protective factors, efforts are underway to identify markers that would be useful for early diagnosis of AD and for charting disease progression or regression in relation to therapeutic interventions. It is generally assumed that the earlier the detection, the greater the likelihood of arresting or reversing the course of AD. Optimally, AD markers would detect the disease early enough to prevent its manifestations. That goal is not as yet within reach, but ongoing research offers hope of achieving it. Below, we group the potential early markers currently being explored under the following 3 headings: cognitive performance, neuroimaging, and other potential early markers.

Cognitive Performance

Mild performance deficits on cognitive tests have been linked to increased risk of dementia in several short-term longitudinal studies of elderly samples.^{140–148} These relationships have fueled attempts to define and characterize preclinical syndromes such as “mild cognitive impairment” (MCI) or “cognitive impairment, no dementia” (CIND) that may be useful for research with elderly samples.^{149,150} There are disagreements among researchers as to how best to interpret such cognitive deficits. Some consider MCI a prodrome of AD or other forms of dementia,¹⁵¹ whereas others point to the variable course and instability of psychometrically defined mild cognitive impairment.¹⁵²

Only a few prospective studies have addressed the question of long-term predictive utility of cognitive tests. These studies have shown statistically significant associations between subclinical cognitive deficits or low levels of cognitive performance and increased risk of dementia across time spans as long as 10 to 20 years.^{153–156} In these studies, baseline cognitive differences are very mild indeed, with mean scores of persons who eventually develop AD often falling in the low-average range. A related investigation, the well known “Nun Study,” documented an association between relatively low-idea density in samples of writing produced at an average age of 22 years and the diagnosis of dementia nearly 6 decades later.¹⁵⁷ None of these studies reported results for AD offspring as a distinct at risk group.

Table 1 lists longitudinal studies with neuropsychologic data on samples known to include AD offspring. The table is limited to US studies in which longitudinal cognitive data were already reported or are in the process of being collected, and it excludes studies that focused exclusively on relatives of patients with early-onset disease.^{164,165} Representative publications are listed, but citations do not include all publications from a given study. To our knowledge, only 2 relatively small studies^{158,159} reported longitudinal cognitive data for first-degree AD relatives and comparable controls without a family history of dementia; both are limited by their use of mixed offspring and sibling samples and retest intervals of only a few years. Additional studies of AD offspring are currently underway.

Several of the investigations summarized in Table 1 provide suggestive evidence that subclinical cognitive differences may be detectable by middle age. However, the relationship of these differences to clinical dementia remains to be clarified, as does the extent to which family history may affect predictive associations. To date, except for 1 small long-term follow-up,¹⁹ longitudinal findings specific to children of AD parents have not been reported, and methods used to determine family history have often not been described. Direct documentation of AD in a parent by autopsy or research level clinical diagnosis is likely to yield a more accurate estimate of the increased risk of disease in offspring than family history interviews alone, particularly for a condition such as AD that may be easily confused with other dementing disorders.¹⁶⁶

If reliable associations can be established between mid-life cognition and later dementia risk, several possible interpretations will need to be considered. Subtle mid-life difficulties with memory or attention could reflect relatively stable cognitive phenotypes that may persist with little change unless the individual begins to develop AD or other dementia. Alternatively, mild cognitive problems may correlate with underlying AD brain pathology (known to be present in mild extent for some individuals by early adulthood and to an increasing extent by age 50 and older), and may, therefore, reflect a true, albeit early, dementia prodrome.⁹⁶ For a discussion of cognitive prodrome vs. phenotype hypotheses, see Greenwood et al¹⁸ and Sliwinski et al.¹⁶⁷

Mid-life cognitive differences may also covary with health or environmental factors, which in themselves may be risk factors for AD.^{157,168–170} Clearly, there is a danger of including individuals with preclinical dementia as “normal controls”.¹⁶⁷ Only long-term prospective studies can clarify the meaning of mid-life cognitive differences, but in the near term, studies that relate cognitive performance to functional neuroimaging or other potential biomarkers are a high priority.

Neuroimaging

Functional neuroimaging methods are among the most promising approaches currently available for identifying possible early AD changes. Although these technologies are relatively new and continue to develop,¹⁷¹ several research groups reported reduced rates of cerebral glucose metabolism (in brain regions known to be affected in AD) among clinically normal middle-aged^{23,25,172} and younger adults with 1 or more *APOE* ϵ 4 alleles. Differentiating patterns have also been documented with functional magnetic resonance imaging (fMRI) for *APOE* ϵ 4 carriers and noncarriers.^{23,173} Added to this are the findings from MRI volumetric studies that show smaller hippocampal size^{174,175} and greater longitudinal decline in hippocampal volume for *APOE* ϵ 4 carriers compared with controls.¹⁷⁶ It has recently been suggested that PIB (Pittsburgh Compound-B) amyloid imaging may be sensitive for detection of a preclinical AD state.^{177,178} One patient came to autopsy 3 months after the PIB scan and the autopsy report confirmed the detection of β -amyloid by PIB.¹⁷⁹ According to the results of another study,¹⁸⁰ 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile-PET (FDDNP) binding may be able to determine regional cerebral patterns of plaques and tangles and potentially distinguish persons with MCI or AD from normal controls. For these and other potential markers, longitudinal followup will be needed to determine how closely outcomes are linked to eventual development of AD.

For the study of AD offspring, 3 recent investigations provide particularly intriguing results. Strong family history effects, independent of *APOE* ϵ 4 genotype, were observed in fMRI activation patterns among asymptomatic children of autopsy-confirmed AD patients²⁶ and in a second, independent sample of AD offspring where parental disease status was determined by autopsy, clinical assessment, or medical record review.¹⁸¹ A third group reported distinctive fMRI findings for cognitively normal middle-aged adults with both an *APOE* ϵ 4 allele and a family history of dementia, compared with persons with neither risk factor.¹⁸² Specific findings have varied with different samples and study procedures. Considered together, however, these recent results suggest that failure to account for family history of AD in research samples may obscure potentially significant clues in the search for early markers of AD.

Other Potential Early Markers

Other potential markers of early AD include total tau in cerebrospinal fluid (CSF), phosphorylated forms of tau in CSF and plasma and also CSF β -amyloid, oligomeric forms

of β -amyloid, and isoprostanes.¹⁸³ In addition to candidate biomarkers, current proteomic and metabolomic technologies hold promise in the identification of formerly unknown biochemical markers of AD.^{184,185} There are many more potential biomarkers for AD and some of these have already been investigated in a preliminary fashion such as plasma homocysteine,¹⁸⁶ CSF sulfatide,¹⁸⁷ α -1-antichymotrypsin,¹⁸⁸ and the ratio of *APP* isoforms in platelets.¹⁸⁹ However, because of the nonspecificity of some of the markers and the variability of others, only CSF markers of tau and β -amyloid have generated sufficient interest and scientific data to be considered viable biomarkers at this stage of development.¹⁹⁰ There is evidence that these CSF measures can be 80% to 90% accurate in establishing the diagnosis of AD versus controls.^{191–193} Given that this rate is similar to what has previously been set as the autopsy standard,^{194–198} this is remarkable progress for a test that is available during life when diagnostic issues are critically important to patients' treatment. However, to establish the predictive value of these and other potential biomarkers, they will have to be studied prospectively over extended periods of time in AD offspring. For example, although detection of PIB binding using nuclear imaging seems to be an indicator of the presence of amyloid pathology, the implications of PIB binding remain undefined for the future development of AD in asymptomatic persons.

Promising research currently underway in this area includes the NIMH's BIOCARD study,¹⁶² the WRAP study,¹⁶ the Washington University Adult Children study,¹² and studies of persons at risk for familial AD.^{20,22,34} As these studies are in their early stages, long-term follow-up data are lacking. Prospective studies of AD offspring over extended periods of time are needed to determine the usefulness of these and other markers not only in early detection of AD but also in prediction of response to treatment and preventive interventions. Combining several possible preclinical markers (eg, amyloid imaging and CSF biomarkers¹⁷⁷ or risk factors¹⁹⁹) to form risk profiles may be an especially powerful method for advancing predictive accuracy.

It is important to bear in mind that many (if not most) of the studies examining the biomarkers mentioned in this section on "Other Potential Early Markers" are restricted to "clean" subjects, that is individuals who are relatively healthy, without a history of head trauma and free from numerous specified medical comorbidities and medications. It is not clear how these selection criteria affected the results and to what extent the findings are applicable to general populations.

RESEARCH RECOMMENDATION

The brief survey provided above leads the authors to make the following recommendation together with 4 implementation strategies:

Devise strategies for assessing genetic and nongenetic risk and protective factors for the development of AD in children of AD parents. Whenever possible, use existing resources to achieve that goal in a cost-efficient and expeditious manner. In particular, utilization of data from prospective studies initiated 40 or more years ago may provide answers to some vital questions within years rather than decades. All strategies will require awareness of methodologic issues and collaboration among researchers at multiple sites to achieve adequate and representative samples. While doing so, consider children of AD parents, together with appropriate controls, as a potentially critical group to recruit for future prevention and intervention studies, especially those doubly at risk by virtue of family history of the disease and specific genotype (eg, *APOE* ϵ 4).

Strategy 1: Use and build on available population studies and data resources, international and national. Organize data sharing with due consideration to ethical and

legal guidelines. Where it is possible to take advantage of existing data archives, results may be achievable within years rather than decades.

- a. Build and maintain a comprehensive inventory of research projects currently studying risk and protective factors in samples that are known to include children of AD parents; identify adult children of AD parents within the samples of existing life course studies that have stockpiled appropriate data and have well-characterized AD in the parent sample; and encourage recruitment of adult children from other studies with well-defined populations that presently may not have a longitudinal design or a specific focus on dementia.
- b. Include siblings and twins in addition to children of AD patients, to assess more thoroughly the effects of family history of AD on the development of AD. Accounting for generational differences and differences in years of vulnerability experienced by siblings as compared with children raises methodologic issues which need to be addressed. For comparative purposes, include children and siblings of parents without AD and without a family history of AD. Include longitudinal data on all participants and their relatives. Be sure to gather information on age or age at death for unaffected family members to fully characterize their status. For some analyses, it will be necessary to develop a repository of data to be used at a future time. For example, to compare risks associated with different first-degree relatives might require all probands and all first-degree relatives to be assessed at comparable ages.
- c. Foster diversity in study populations, building on existing resources [eg, Sacramento Area Longitudinal Study on Aging (SALSA), WHICAP, Chicago Health and Aging Study, Indianapolis-Ibadan Study, ADAMS, the Alzheimer's Disease Research Centers (ADRCs) and Alzheimer's Disease Core Centers (ADCCs)].
- d. Form a working group to review research design options and prioritize those research approaches that can evaluate the importance of family history in AD risk, within budget, time, and policy constraints, while controlling for other risk factors.

Strategy 2: Identify a common core of assessment procedures useful for the study of risk and protective factors, keeping instruments as brief as possible, whereas maintaining awareness of, and adapting to scientific advances whenever indicated.

- a. Develop consensus regarding criteria for confirming AD in participants' parents. To maximize the yield from existing data, it may be useful for researchers to rank the likelihood that a study participant has a parent with AD on the basis of a continuum of certainty ranging from autopsy confirmation through research level clinical evaluation, review of existing medical records, and questionnaire or interview. Although each of these methods may yield useful information, prospectively documenting AD in a parent, using contemporary criteria, promises to more accurately reflect disease state than obtaining a family history based only on recall of events that occurred years, if not decades, earlier.
- b. Develop consensus regarding criteria for selecting controls to compare with children of AD parents. A ranking of likelihood that a study participant's parents did not have AD or other dementia may also be useful, as the apparent absence of AD is highly linked to longevity and may be subject to other

detection biases. Ideally, the controls selected will have had both parents live for at least as long as the parents of the at risk offspring. Having access to current diagnoses, or autopsy diagnoses, would clearly improve ascertainment of controls.

- c. Develop consensus regarding standardized collection of a common core of information on family history of dementia, race, ethnicity, and ancestry, and current and past lifestyle information (eg, medical, psychiatric, diet, medications, supplements, toxic exposures, mental and social stimulation, exercise, education, and occupation), on the basis of comprehensive review of existing questionnaires and interview methods.

Strategy 3: Explore the usefulness of preclinical changes in biologic measures, especially cognitive and neuroimaging, as early markers of AD.

- a. Develop consensus regarding a common core of cognitive assessment instruments (or categories of instruments) useful for the study of preclinical change (eg, measures of memory and executive function, indices of literacy, quality and amount of education), that may be needed to adequately interpret results. Consideration should be given to identifying a small core of standardized tests that could be used across different studies and would be appropriate for ethnically and linguistically diverse populations. This core battery would be similar in principle to the Uniform Data Set²⁰⁰ neuropsychologic battery of the ADRC and ADCC protocols, but should include measures that are sufficiently challenging to detect small performance differences in higher functioning at risk samples. Incorporation of a small number of experimental measures to increase sensitivity to subtle preclinical changes should also be considered.
- b. Develop consensus regarding a common core of functional neuroimaging measures. Long-term longitudinal data on neuroimaging changes are lacking because some neuroimaging technologies have only recently been developed. It is important to determine what type of neuroimaging information exists in current databases and to incorporate neuroimaging measures into existing and new longitudinal studies of adult children of AD parents.
- c. Develop consensus regarding the inclusion of a common core of biologic samples (eg, DNA, plasma, serum, urine, CSF, and lymphoblastoid cell lines) of highest priority for the study of AD offspring, specifying the goals of each type of sample. In the interest of efficiency and cost effectiveness, and keeping demands on research participants within reasonable limits, investigators will have to agree on a relatively small number of samples.

Strategy 4: Use all available analytic methods to address potential interactions between genetic and other risk and protective factors²⁰¹.

- a. Encourage joint analysis of data from separate studies, including international and national resources.
- b. Develop consensus on risk profiles, using information from multiple domains. In constructing such profiles, pay attention to parental AAO of AD and to the timing of exposure to putative risk and protective factors within the life courses.
- c. Encourage testing of varying theoretical models of change, taking into account issues of temporal and longitudinal design.

CONCLUSIONS

Millions of children whose parents developed AD spend much of their adult lives wondering whether their future will include a fate like that endured by their parents. Despite the plethora of carefully conducted research studies, we still cannot predict with a satisfactory degree of certainty as to who among them will fall victim to the dreaded disease, nor even how many of them will eventually become afflicted. We do know that the risk of dementia increases exponentially with age. Most other suggested risk and protective factors still lack the robust data required for devising effective preventive and treatment interventions. Early markers to reliably identify vulnerable individuals are urgently needed. At risk individuals may benefit from current trials (www.alz.org) of potentially disease-modifying interventions. These trials depend on the voluntary participation of families with AD.

Although cross-sectional studies may be useful to determine if a given marker varies with genetic and/or other risk factors, prospective longitudinal investigations are needed to address the predictive value of putative AD markers and the time course to symptom expression. A handful of such studies are now underway, and given the age structure of the samples being studied, they may begin to provide a preliminary picture of risks to AD children within the next decade. If investigators involved in other ongoing longitudinal studies were to determine which of their participants are (or are not) offspring of parents with AD, this could greatly enlarge the pool of subjects and help to fast-track answers to at least some of the questions we identified. However, collaborative prospective, longitudinal studies achieving sufficiently large sample sizes, and using appropriate methodologies will allow us to take another step forward, that is to explore the complex interactions between individual vulnerabilities (genetic and nongenetic) and specific environmental variables. It is important to emphasize that, because of genetic-environmental interactions, the risk and protective factors identified within the general population may not apply to people with a family history of AD, or may operate in a different way. In view of mounting evidence of mid-life¹⁶⁸ and even earlier^{157,169,170} risk factors for dementia, it will be important for some prospective studies to focus on these younger phases of life.

Clearly, further studies with AD offspring are bound to yield valuable insights. Because of the scientific discoveries of the past decades, the methodologies have become available. Now is the time to take advantage of them. For this reason, it is vitally important for children of AD parents to volunteer for research. It is precisely because of our lack of knowledge about risk and protective factors specific to this population that their help as research participants is potentially invaluable. While awaiting results of ongoing research, we urge the children of persons with AD to practice the lifestyle habits that promote good overall health and might perhaps reduce the risk of manifesting AD. We urge our colleagues to participate in initiating the much needed research outlined above.

Acknowledgments

This paper was inspired by the Workshop "Children of Alzheimer Parent-What Are the Risks?" held in San Diego, CA, March 6th and 7th, 2005. Elvira Jimenez, MPH, provided invaluable assistance to the conference and this manuscript and especially its bibliographic aspects. The critical acumen and editing skills of Petra Hammerl-Mistry, MA, helped shape this manuscript at various stages of its development. The authors gratefully acknowledge their contributions.

Financial support was received from the Albert Parvin Foundation and the Lon V. Smith Foundation to the UCLA/WLAVA Family Study of Alzheimer Disease (L.J.); NIA grant to ADRC 5 P50 AG05134 (D.B.); NIA grant R01 AG08724 to the Study of Dementia in Swedish Twins (M.G.); NIA grant P50 AG16573 to ADRC (C.K.); NIA grant P01 AG026276 to the Washington University Adult Children Study (J.C.M.); NIA K08AG-22228 and P01 AG-1657 (J.M.R.); the Larry L. Hillblom Foundation and Turken Foundation (L.E.); NIA grant AG08549 to the Duke Twins Study of Memory in Aging (B.L.P.); NHGRI/NIA grant R01 HG/AG 02213 to the REVEAL Study (J.S.R.); NHLBI grant HL51429 and NIA grant AG09341 (G.E.S.); and NIA grants 5R01 AG08122 to the

Epidemiology of Dementia in the Framingham Study and 5R01 AG16495 to the MRI, Genetic, and Cognitive Precursors of AD and Dementia Study (P.A.W.); and the NIA Intramural Research Program of the NIH contributed to the support of this research (A.B.Z.).

REFERENCES

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychiatrisch-Gerichtliche Medizin. 1907; 64:146–148. reprinted with translation by L. Jarvik and H. Greenson. About a peculiar disease of the cerebral cortex. *Alzheimer Dis Assoc Disord*. 1987; 13–18.
2. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Chicago, Illinois: 2007.
3. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. *JAMA*. 1989; 262:2551–2556. [PubMed: 2810583]
4. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *Am J Public Health*. 1998; 88:1337–1342. [PubMed: 9736873]
5. United States General Accounting Office. Alzheimer's disease: Estimates of prevalence in the United States. <http://www.gao.gov/archive/1998/he98016.pdf>.
6. Plassman BL, Langa KM, Fisher GG, et al. The prevalence of dementia in the United States: the Aging, Demographics, and memory Study. *Neuroepidemiology*. 2007; 29:125–132. [PubMed: 17975326]
7. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer's disease. *Alzheimers Dement*. 2007; 3:186–191.
8. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005; 366:2112–2117. [PubMed: 16360788]
9. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. *Drugs Aging*. 1999; 15:365–375. [PubMed: 10600044]
10. Cummings JL. Alzheimer's disease. *N Engl J Med*. 2004; 351:56–67. [PubMed: 15229308]
11. Jarvik LF, Matsuyama SS. Two decades of research in Alzheimer disease: looking back to the first volume of ADAD. *Alzheimer Dis Assoc Disord*. 2006; 20:3–5. [PubMed: 16493229]
12. Coats M, Morris JC. Antecedent biomarkers of Alzheimer's disease: the adult children study. *J Geriatr Psychiatry Neurol*. 2005; 18:242–244. [PubMed: 16306247]
13. Mayeux R, Small SA, Tang M, et al. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. *Neurobiol Aging*. 2001; 22:683–689. [PubMed: 11445269]
14. Jarvik LF, Blazer D. Children of Alzheimer patients: an overview. *J Geriatr Psychiatry Neurol*. 2005; 18:181–186. [PubMed: 16306236]
15. Roberts JS, Cupples LA, Relkin NR, et al. Genetic risk assessment for adult children of people with Alzheimer's disease: the risk evaluation and education for Alzheimer's disease (REVEAL) study. *J Geriatr Psychiatry Neurol*. 2005; 18:250–255. [PubMed: 16306249]
16. Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. *J Geriatr Psychiatry Neurol*. 2005; 18:245–249. [PubMed: 16306248]
17. Wolf, PA.; Au, R.; Beiser, A., et al. Cognitive Performance and Quantitative Brain MRI in AD Offspring of Parents With and Without AD and Dementia: The Framingham Study. San Diego: American Association for Geriatric Psychiatry; 2005.
18. Greenwood PM, Lambert C, Sunderland T, et al. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results from the National Institute of Mental Health's BIOCARD study. *Neuropsychology*. 2005; 19:199–211. [PubMed: 15769204]
19. Jarvik LF, La Rue A, Gokhman I, et al. Middle-aged children of Alzheimer parents, a pilot study: stable neurocognitive performance at 20-year follow-up. *J Geriatr Psychiatry Neurol*. 2005; 18:187–191. [PubMed: 16306237]

20. Moonis M, Swearer JM, Dayaw MP, et al. Familial Alzheimer disease: decreases in CSF Aβ₄₂ levels precede cognitive decline. *Neurology*. 2005; 65:323–325. [PubMed: 16043812]
21. Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, et al. Neuropsychological function in nondemented carriers of presenilin-1 mutations. *Neurology*. 2005; 65:552–558. [PubMed: 16116115]
22. Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. *Ann Neurol*. 2003; 53:181–188. [PubMed: 12557284]
23. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. *N Engl J Med*. 2000; 343:450–456. [PubMed: 10944562]
24. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ε4 allele. *Neurology*. 2004; 62:1990–1995. [PubMed: 15184602]
25. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. *N Engl J Med*. 1996; 334:752–758. [PubMed: 8592548]
26. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. *Proc Natl Acad Sci USA*. 2000; 97:6037–6042. [PubMed: 10811879]
27. Bassett SS, Yousem DM, Cristinzio C, et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. *Brain*. 2006; 129(Pt 5):1229–1239. [PubMed: 16627465]
28. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: what is in store for the oldest old? *Neurology*. 1996; 46:641–650. [PubMed: 8618660]
29. Lee JH, Flaquer A, Stern Y, et al. Genetic influences on memory performance in familial Alzheimer disease. *Neurology*. 2004; 62:414–421. [PubMed: 14872023]
30. Payami H, Grimsli H, Oken B, et al. A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. *Am J Hum Genet*. 1997; 60:948–956. [PubMed: 9106542]
31. Silverman JM, Smith CJ, Marin DB, et al. Familial patterns of risk in very late-onset Alzheimer disease. *Arch Gen Psychiatry*. 2003; 60:190–197. [PubMed: 12578437]
32. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006; 63:168–174. [PubMed: 16461860]
33. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. *Neurology*. 2000; 54(11 suppl 5):S10–S15. [PubMed: 10854355]
34. McMurtry AM, Ringman J, Chao SZ, et al. Family history of dementia in early-onset versus very late-onset Alzheimer's disease. *Int J Geriatr Psychiatry*. 2006; 21:597–598. [PubMed: 16783800]
35. Silverman JM, Ciresi G, Smith CJ, et al. Variability of familial risk of Alzheimer disease across the late life span. *Arch Gen Psychiatry*. 2005; 62:565–573. [PubMed: 15867110]
36. Freimer N, Sabatti C. The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology. *Nat Genet*. 2004; 36:1045–1051. [PubMed: 15454942]
37. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet*. 2007; 39:17–23. [PubMed: 17192785]
38. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? *Hum Mol Genet*. 2004; 13(Spec No 1):R135–R141. [PubMed: 14764623]
39. Bird TD. Genetic factors in Alzheimer's disease. *N Engl J Med*. 2005; 352:862–864. [PubMed: 15745976]
40. Daw EW, Payami H, Nemens EJ, et al. The number of trait loci in late-onset Alzheimer disease. *Am J Hum Genet*. 2000; 66:196–204. [PubMed: 10631151]
41. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. *JAMA*. 1995; 273:1354–1359. [PubMed: 7715060]
42. Kamboh MI. Molecular genetics of late-onset Alzheimer's disease. *Ann Hum Genet*. 2004; 68(Pt 4):381–404. [PubMed: 15225164]

43. Wijsman EM, Daw EW, Yu CE, et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. *Am J Hum Genet.* 2004; 75:398–409. [PubMed: 15248153]
44. Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. *Proc Natl Acad Sci U S A.* 1985; 82:8729–8732. [PubMed: 2934737]
45. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature.* 1991; 349:704–706. [PubMed: 1671712]
46. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. *Science.* 1992; 258:668–671. [PubMed: 1411576]
47. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. *Hum Mol Genet.* 1996; 5:985–988. [PubMed: 8817335]
48. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med.* 1996; 2:864–870. [PubMed: 8705854]
49. Mann, D. Down's Syndrome and Alzheimer's Disease. In: Esiri, MM.; Lee, VM-Y.; Trojanowski, JQ., editors. *The Neuropathology of Dementia.* 2nd ed.. Cambridge, UK: Cambridge University Press; 2004. p. 207-226.
50. Tsuang, D.; Bird, DT. Genetics of dementia. In: Sadavoy, J.; Jarvik, LF.; Grossberg, G., et al., editors. *Comprehensive Textbook of Geriatric Psychiatry.* 3rd ed.. New York: WW: Norton; 2004. p. 39-84.
51. Morris JC. Dementia update 2005. *Alzheimer Dis Assoc Disord.* 2005; 19:100–117. [PubMed: 15942329]
52. Roberson ED, Searce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science.* 2007; 316:750–754. [PubMed: 17478722]
53. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA.* 2000; 97:2892–2897. [PubMed: 10694577]
54. Raber J, Wong D, Buttini M, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. *Proc Natl Acad Sci USA.* 1998; 95:10914–10919. [PubMed: 9724804]
55. The International HapMap Consortium. A haplotype map of the human genome. *Nature.* 2005; 437:1299–1320. [PubMed: 16255080]
56. Ashford JW, Mortimer JA. Non-familial Alzheimer's disease is mainly due to genetic factors. *J Alzheimers Dis.* 2002; 4:169–177. [PubMed: 12226536]
57. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. *Neurology.* 1999; 53:321–331. [PubMed: 10430421]
58. National Institute on Aging. Rockville, MD: National Institutes of Health; 1995. Progress Report on AD.
59. Small BJ, Rosnick CB, Fratiglioni L, et al. Apolipoprotein E and cognitive performance: a meta-analysis. *Psychol Aging.* 2004; 19:592–600. [PubMed: 15584785]
60. Zuo L, van Dyck CH, Luo X, et al. Variation at APOE and STH loci and Alzheimer's disease. *Behav Brain Funct.* 2006; 2:13. [PubMed: 16603077]
61. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA.* 1997; 278:1349–1356. [PubMed: 9343467]
62. Henderson AS, Eastel S, Jorm AF, et al. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. *Lancet.* 1995; 346:1387–1390. [PubMed: 7475820]
63. Manly, JJ.; Mayeux, R. Ethnic differences in dementia and Alzheimer's disease. In: Anderson, NA.; Bulatao, RA.; Cohen, B., editors. *Critical Perspectives on Racial and Ethnic Differentials in Health in Late Life.* Washington, DC: National Academies Press; 2004.

64. Faison WE, Schultz SK, Aerssens J, et al. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. *Int Psychogeriatr*. 2007; 19:539–558. [PubMed: 17451614]
65. Fillenbaum GG, Heyman A, Huber MS, et al. Performance of elderly African American and White community residents on the CERAD Neuropsychological Battery. *J Int Neuropsychol Soc*. 2001; 7:502–509. [PubMed: 11396552]
66. Manly JJ, Jacobs DM, Sano M, et al. Cognitive test performance among nondemented elderly African Americans and whites. *Neurology*. 1998; 50:1238–1245. [PubMed: 9595969]
67. Liu HC, Hong CJ, Wang SJ, et al. ApoE genotype in relation to AD and cholesterol: a study of 2326 Chinese adults. *Neurology*. 1999; 53:962–966. [PubMed: 10496253]
68. Zhang ZX, Zahner GE, Roman GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. *Arch Neurol*. 2005; 62:447–453. [PubMed: 15767510]
69. Lai S, Chen Y, Wen Z. Association between apolipoprotein E polymorphism and Alzheimer's disease: a population-based study in Guangzhou, China. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2001; 22:202–204. Article in Chinese. [PubMed: 11860878]
70. Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. *Ann Neurol*. 2006; 59:182–185. [PubMed: 16278853]
71. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. *Arch Neurol*. 2003; 60:185–189. [PubMed: 12580702]
72. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. *Ann Neurol*. 1995; 37:118–120. [PubMed: 7818244]
73. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. *JAMA*. 1998; 279:751–755. [PubMed: 9508150]
74. Devi G, Ottman R, Tang M, et al. Influence of APOE genotype on familial aggregation of AD in an urban population. *Neurology*. 1999; 53:789–794. [PubMed: 10489042]
75. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. *JAMA*. 2002; 287:329–336. [PubMed: 11790212]
76. Sahota A, Yang M, Gao S, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. *Ann Neurol*. 1997; 42:659–661. [PubMed: 9382479]
77. Bowirrat A, Friedland RP, Chapman J, et al. The very high prevalence of AD in an Arab population is not explained by APOE epsilon4 allele frequency. *Neurology*. 2000; 55:731. [PubMed: 10980749]
78. Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. *Neurology*. 2000; 54:240–242. [PubMed: 10636159]
79. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. *Ann Hum Biol*. 2006; 33:279–308. [PubMed: 17092867]
80. Masters CL, Beyreuther K. Alzheimer's disease. *BMJ*. 1998; 316:446–448. [PubMed: 9492674]
81. Mayeux R. Gene-environment interaction in late-onset Alzheimer disease: the role of apolipoprotein-epsilon4. *Alzheimer Dis Assoc Disord*. 1998; 12(suppl 3):S10–S15. [PubMed: 9876937]
82. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. *Ann Neurol*. 1995; 38:6–14. [PubMed: 7611727]
83. Tschanz JT, Treiber K, Norton MC, et al. A population study of Alzheimer's disease: findings from the Cache County Study on memory, health, and aging. *Care Manag J*. 2005; 6:107–114. [PubMed: 16544872]
84. Pitner JK, Bachman DL. A synopsis of the practice parameters on dementia from the American Academy of Neurology on the diagnosis of dementia. *Consult Pharm*. 2004; 19:52–63. [PubMed: 16553467]

85. Cupples LA, Farrer LA, Sadovnick AD, et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. *Genet Med*. 2004; 6:192–196. [PubMed: 15266206]
86. Farrer LA, Cupples LA, van Duijn CM, et al. Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. *Ann Neurol*. 1995; 38:797–808. [PubMed: 7486872]
87. Khachaturian AS, Corcoran CD, Mayer LS, et al. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. *Arch Gen Psychiatry*. 2004; 61:518–524. [PubMed: 15123497]
88. Miech RA, Breitner JC, Zandi PP, et al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. *Neurology*. 2002; 58:209–218. [PubMed: 11805246]
89. Ewbank DC. The APOE gene and differences in life expectancy in Europe. *J Gerontol A Biol Sci Med Sci*. 2004; 59:16–20. [PubMed: 14718482]
90. McArdle JJ, Small BJ, Backman L, et al. Longitudinal models of growth and survival applied to the early detection of Alzheimer's disease. *J Geriatr Psychiatry Neurol*. 2005; 18:234–241. [PubMed: 16306246]
91. Hayden KM, Zandi PP, Lyketsos CG, et al. Apolipoprotein E genotype and mortality: findings from the Cache County Study. *J Am Geriatr Soc*. 2005; 53:935–942. [PubMed: 15935014]
92. Rogava E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet*. 2007; 39:168–177. [PubMed: 17220890]
93. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. *Neuron*. 2007; 54:713–720. [PubMed: 17553421]
94. Swan GE, Lessov-Schlaggar CN, Carmelli D, et al. Apolipoprotein E epsilon4 and change in cognitive functioning in communitydwelling older adults. *J Geriatr Psychiatry Neurol*. 2005; 18:196–201. [PubMed: 16306239]
95. Bennett DA, Wilson RS, Schneider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. *Neurology*. 2003; 60:1909–1915. [PubMed: 12821732]
96. Mortimer JA, Borenstein AR, Gosche KM, et al. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. *J Geriatr Psychiatry Neurol*. 2005; 18:218–223. [PubMed: 16306243]
97. Oddo S, Caccamo A, Green KN, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. *Proc Natl Acad Sci USA*. 2005; 102:3046–3051. [PubMed: 15705720]
98. Tyas SL, White LR, Petrovitch H, et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. *Neurobiol Aging*. 2003; 24:589–596. [PubMed: 12714116]
99. Petot GJ, Friedland RP. Lipids, diet and Alzheimer disease: an extended summary. *J Neurol Sci*. 2004; 226:31–33. [PubMed: 15537515]
100. Scarmeas N, Stern Y, Tang MX, et al. Mediterranean diet and risk for Alzheimer's disease. *Ann Neurol*. 2006; 59:912–921. [PubMed: 16622828]
101. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. *Arch Neurol*. 2003; 60:940–946. [PubMed: 12873849]
102. Dai Q, Borenstein AR, Wu Y, et al. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. *Am J Med*. 2006; 119:751–759. [PubMed: 16945610]
103. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA*. 2002; 287:3223–3229. [PubMed: 12076218]
104. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. *Arch Neurol*. 2004; 61:82–88. [PubMed: 14732624]
105. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. *Am J Clin Nutr*. 2005; 82:636–643. [PubMed: 16155278]
106. Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer disease. *Arch Neurol*. 2003; 60:194–200. [PubMed: 12580703]

107. Luchsinger JA, Tang MX, Shea S, et al. Caloric intake and the risk of Alzheimer disease. *Arch Neurol.* 2002; 59:1258–1263. [PubMed: 12164721]
108. Middleton LE, Kirkland SA, Maxwell CJ, et al. Exercise: a potential contributing factor to the relationship between folate and dementia. *J Am Geriatr Soc.* 2007; 55:1095–1098. [PubMed: 17608885]
109. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. *Trends Neurosci.* 2002; 25:295–301. [PubMed: 12086747]
110. Crowe M, Andel R, Pedersen NL, et al. Does participation in leisure activities lead to reduced risk of Alzheimer's disease? A prospective study of Swedish twins. *J Gerontol B Psychol Sci Soc Sci.* 2003; 58:249–255.
111. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. *N Engl J Med.* 2003; 348:2508–2516. [PubMed: 12815136]
112. Wilson RS, Mendes De Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. *JAMA.* 2002; 287:742–748. [PubMed: 11851541]
113. Andel R, Crowe M, Pedersen NL, et al. Complexity of work and risk of Alzheimer's disease: a population-based study of Swedish twins. *J Gerontol B Psychol Sci Soc Sci.* 2005; 60:251–258.
114. Potter GG, Helms MJ, Burke JR, et al. Job demands and dementia risk among male twin pairs. *Alzheimers Dement.* 2007; 3:192–199.
115. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. *Neurology.* 1998; 50:164–168. [PubMed: 9443474]
116. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. *J Gerontol A Biol Sci Med Sci.* 2004; 59:178–183. discussion 184–192. [PubMed: 14999034]
117. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70–81 years. *BMJ.* 2004; 328:548. [PubMed: 14980984]
118. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. *Exp Gerontol.* 2003; 38:941–946. [PubMed: 12954480]
119. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu- Asia Aging Study. *Diabetes.* 2002; 51:1256–1262. [PubMed: 11916953]
120. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. *J Clin Psychiatry.* 2004; 65:634–651. quiz 730. [PubMed: 15163249]
121. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Arch Neurol.* 2004; 61:661–666. [PubMed: 15148141]
122. Haan MN, Mungas DM, Gonzalez HM, et al. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. *J Am Geriatr Soc.* 2003; 51:169–177. [PubMed: 12558712]
123. Kumari M, Brunner E, Fuhrer R. Minireview: mechanisms by which the metabolic syndrome and diabetes impair memory. *J Gerontol A Biol Sci Med Sci.* 2000; 55:B228–B232. [PubMed: 10819309]
124. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. *Neurology.* 1999; 53:1937–1942. [PubMed: 10599761]
125. Wu JH, Haan MN, Liang J, et al. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. *Ann Epidemiol.* 2003; 13:369–376. [PubMed: 12821276]
126. Wu JH, Haan MN, Liang J, et al. Diabetes as a predictor of change in functional status among older Mexican Americans: a population-based cohort study. *Diabetes Care.* 2003; 26:314–319. [PubMed: 12547855]
127. Small SA. The longitudinal axis of the hippocampal formation: its anatomy, circuitry, and role in cognitive function. *Rev Neurosci.* 2002; 13:183–194. [PubMed: 12160261]

128. Reaven, GM.; Laws, A. Insulin Resistance: The Metabolic Syndrome X. Totowa, NJ: Humana Press; 1999.
129. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. *Am J Pathol.* 1998; 153:1149–1155. [PubMed: 9777946]
130. Park CR. Cognitive effects of insulin in the central nervous system. *Neurosci Biobehav Rev.* 2001; 25:311–323. [PubMed: 11445137]
131. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol.* 2001; 154:635–641. [PubMed: 11581097]
132. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. *BMJ.* 1997; 315:1045–1049. [PubMed: 9366728]
133. Scacchi R, De Bernardini L, Mantuano E, et al. DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease. *Dement Geriatr Cogn Disord.* 1998; 9:186–190. [PubMed: 9681639]
134. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. *Lancet.* 2000; 356:1627–1631. [PubMed: 11089820]
135. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, cognitive function in older women. *Arch Neurol.* 2002; 59:378–384. [PubMed: 11890840]
136. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. *JAMA.* 1999; 282:254–260. [PubMed: 10422994]
137. Mungall MM, Gaw A, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? *Drugs Aging.* 2003; 20:263–275. [PubMed: 12641482]
138. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. *Alzheimer Dis Assoc Disord.* 2006; 20:63–72. [PubMed: 16493239]
139. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology.* 2007; 68:1800–1808. [PubMed: 17460158]
140. Albert MS, Moss MB, Tanzi R, et al. Preclinical prediction of AD using neuropsychological tests. *J Int Neuropsychol Soc.* 2001; 7:631–639. [PubMed: 11459114]
141. Backman L, Jones S, Berger AK, et al. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. *Neuropsychology.* 2005; 19:520–531. [PubMed: 16060827]
142. Bondi MW, Monsch AU, Galasko D, et al. Preclinical cognitive markers of dementia of the Alzheimer type. *Neuropsychology.* 1994; 8:374–384.
143. Grober E, Kawas C. Learning and retention in preclinical and early Alzheimer's disease. *Psychol Aging.* 1997; 12:183–188. [PubMed: 9100279]
144. Jacobs DM, Sano M, Dooneief G, et al. Neuropsychological detection and characterization of preclinical Alzheimer's disease. *Neurology.* 1995; 45:957–962. [PubMed: 7746414]
145. Masur DM, Sliwinski M, Lipton RB, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. *Neurology.* 1994; 44:1427–1432. [PubMed: 8058143]
146. Petersen RC, Smith GE, Ivnik RJ, et al. Memory function in very early Alzheimer's disease. *Neurology.* 1994; 44:867–872. [PubMed: 8190289]
147. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. *Arch Neurol.* 1998; 55:395–401. [PubMed: 9520014]
148. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. *Arch Gen Psychiatry.* 2006; 63:916–924. [PubMed: 16894068]
149. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med.* 2004; 256:240–246. [PubMed: 15324367]

150. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. *Arch Neurol.* 2005; 62:1160–1163. discussion 1167. [PubMed: 16009779]
151. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. *Arch Neurol.* 2001; 58:397–405. [PubMed: 11255443]
152. Ganguli M, Dodge HH, Shen C, et al. Mild cognitive impairment, amnesic type: an epidemiologic study. *Neurology.* 2004; 63:115–121. [PubMed: 15249620]
153. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. *Arch Neurol.* 2000; 57:808–813. [PubMed: 10867777]
154. Kawas CH, Corrada MM, Brookmeyer R, et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. *Neurology.* 2003; 60:1089–1093. [PubMed: 12682311]
155. La Rue A, Jarvik LF. Reflections of biological changes in the psychological performance of the aged. *Age.* 1980; 3:29–32.
156. La Rue A, Jarvik LF. Cognitive function and prediction of dementia in old age. *Int J Aging Hum Dev.* 1987; 25:79–89. [PubMed: 3436685]
157. Snowdon DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. *JAMA.* 1996; 275:528–532. [PubMed: 8606473]
158. La Rue A, O'Hara R, Matsuyama SS, et al. Cognitive changes in young-old adults: effect of family history of dementia. *J Clin Exp Neuropsychol.* 1995; 17:65–70. [PubMed: 7608303]
159. Small GW, Okonek A, Mandelkern MA, et al. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. *Int Psychogeriatr.* 1994; 6:23–44. discussion 60–62. [PubMed: 8054492]
160. Miller KJ, Rogers SA, Siddarth P, et al. Object naming and semantic fluency among individuals with genetic risk for Alzheimer's disease. *Int J Geriatr Psychiatry.* 2005; 20:128–136. [PubMed: 15660408]
161. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc Natl Acad Sci USA.* 2004; 101:284–289. [PubMed: 14688411]
162. Greenwood PM, Sunderland T, Putnam K, et al. Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: results from the NIMH BIOCARD study. *Neuropsychology.* 2005; 19:830–840. [PubMed: 16351359]
163. Levy JA, Bergeson J, Putnam K, et al. Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. *J Int Neuropsychol Soc.* 2004; 10:362–370. [PubMed: 15147594]
164. Fox NC, Warrington EK, Seiffer AL, et al. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. *Brain.* 1998; 121(Pt 9): 1631–1639. [PubMed: 9762953]
165. Ringman JM. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. *J Geriatr Psychiatry Neurol.* 2005; 18:228–233. [PubMed: 16306245]
166. Murabito JM, Nam BH, D'Agostino RB Sr, et al. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. *Ann Intern Med.* 2004; 140:434–440. [PubMed: 15023709]
167. Sliwinski M, Lipton RB, Buschke H, et al. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. *J Gerontol B Psychol Sci Soc Sci.* 1996; 51:217–225.
168. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *BMJ.* 2001; 322:1447–1451. [PubMed: 11408299]
169. Richards M, Sacker A. Lifetime antecedents of cognitive reserve. *J Clin Exp Neuropsychol.* 2003; 25:614–624. [PubMed: 12815499]
170. Whalley LJ, Starr JM, Athawes R, et al. Childhood mental ability and dementia. *Neurology.* 2000; 55:1455–1459. [PubMed: 11094097]

171. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. *Arch Neurol*. 2006; 63:693–699. [PubMed: 16682538]
172. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. *Proc Natl Acad Sci USA*. 2005; 102:8299–8302. [PubMed: 15932949]
173. Bondi MW, Houston WS, Eyler LT, et al. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. *Neurology*. 2005; 64:501–508. [PubMed: 15699382]
174. Cohen RM, Small C, Lalonde F, et al. Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women. *Neurology*. 2001; 57:2223–2228. [PubMed: 11756601]
175. Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. *Ann Neurol*. 1998; 44:288–291. [PubMed: 9708558]
176. Moffat SD, Szekely CA, Zonderman AB, et al. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. *Neurology*. 2000; 55:134–136. [PubMed: 10891924]
177. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol*. 2006; 59:512–519. [PubMed: 16372280]
178. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry*. 2002; 10:24–35. [PubMed: 11790632]
179. Bacsikai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. *Arch Neurol*. 2007; 64:431–434. [PubMed: 17353389]
180. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. *N Engl J Med*. 2006; 355:2652–2663. [PubMed: 17182990]
181. Johnson SC, Schmitz TW, Trivedi MA, et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. *J Neurosci*. 2006; 26:6069–6076. [PubMed: 16738250]
182. Fleisher AS, Houston WS, Eyler LT, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. *Arch Neurol*. 2005; 62:1881–1888. [PubMed: 16344346]
183. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group: NIA initiative on neuroimaging in Alzheimer's disease. *Neurobiol Aging*. 2003; 24:521–536. [PubMed: 12714109]
184. Papassotiropoulos A, Fountoulakis M, Duncley T, et al. Genetics, transcriptomics, and proteomics of Alzheimer's disease. *J Clin Psychiatry*. 2006; 67:652–670. [PubMed: 16669732]
185. Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. *Arch Neurol*. 2007; 64:366–370. [PubMed: 17353378]
186. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med*. 2002; 346:476–483. [PubMed: 11844848]
187. Han X, Fagan AM, Cheng H, et al. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. *Ann Neurol*. 2003; 54:115–119. [PubMed: 12838527]
188. Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. *Neurology*. 2005; 64:1371–1377. [PubMed: 15851726]
189. Baskin F, Rosenberg RN, Iyer L, et al. Platelet APP isoform ratios correlate with declining cognition in AD. *Neurology*. 2000; 54:1907–1909. [PubMed: 10822427]
190. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biol Psychiatry*. 2004; 56:670–676. [PubMed: 1552251]
191. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. *Arch Neurol*. 1998; 55:937–945. [PubMed: 9678311]
192. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *Neuro Rx*. 2004; 1:213–225. [PubMed: 15717022]

193. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. *JAMA*. 2003; 289:2094–2103. [PubMed: 12709467]
194. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. *J Am Geriatr Soc*. 1999; 47:564–569. [PubMed: 10323650]
195. Mendez MF, Mastri AR, Sung JH, et al. Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. *Alzheimer Dis Assoc Disord*. 1992; 6:35–43. [PubMed: 1605942]
196. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991; 41:479–486. [PubMed: 2011243]
197. Newell KL, Hyman BT, Growdon JH, et al. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. *J Neuropathol Exp Neurol*. 1999; 58:1147–1155. [PubMed: 10560657]
198. Jarvik LF, Matsuyama SS, Chui H, et al. Autopsy diagnoses of Alzheimer disease: independent reviews and clinical implications. *Int J Geriatr Psychiatry*. 1995; 10:505–510.
199. Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol*. 2006; 5:735–741. [PubMed: 16914401]
200. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. *Alzheimer Dis Assoc Disord*. 2006; 20:210–216. [PubMed: 17132964]
201. Martin GM. Molecular mechanisms of late life dementias. *Exp Gerontol*. 2000; 35:439–443. [PubMed: 10959031]

TABLE 1

Neuropsychologic Findings of Prospective Longitudinal Studies That Include First-degree Relatives of Persons With Alzheimer's Disease

Sample	Design/Procedures	Results/Comments
UCSD ADRC group ¹⁴² Nondemented elderly (mean age = 70 y), including some first-degree AD relatives	Cognitive results were based on short-term test-retest (three 1-y testings). This research group has also studied fMRI as a function of family history	AD relatives scored lower on verbal list learning measures, and 4 of 5 who converted to dementia in 3 y were AD relatives. Small sample and limited follow-up
UCLA/West LA VA Family Study of Alzheimer Disease ^{19,158} Nondemented first-degree AD relatives, young adult to middle-aged and matched controls without a family history of dementia. Above-average education	This study reported short-term cognitive test-retest (2 to 4 y) results for AD relatives versus controls, and 20-y cognitive outcomes for a small convenience sample (N = 25) of AD children that increased in age from 41 to 61 y; 44% were APOE ϵ 4 positive	On short-term retest, a higher proportion of AD relatives showed cognitive decline than controls. Relatives of early-onset AD patients declined the most. At long-term follow-up, scores of AD children were generally stable compared with initial test scores and age norms. Small sample, limited follow-up, no controls reported for long-term follow-up
Family Studies of Alzheimer Disease (UCLA) ^{159,160} Nondemented healthy adults, mean age 60 to 65 y, including some first-degree AD relatives. Highly screened samples, high IQ and education	This research group has reported baseline cognitive data for family history negative and positive subjects, MRI and PET FDG, and short-term test-retest (2 y) results	Negligible familial vs. nonfamilial cognitive differences at baseline, despite some PET FDG differences. At retest, family history of AD predicted decline on a semantic retrieval task. Small samples and limited follow-up
U. Arizona/Mayo-Scottsdale ^{24,161} Nondemented ϵ 4 carriers vs. noncarriers, middle-aged. Most subjects had first-degree relatives with AD	This research group has reported short-term test-retest (2 to 3 y) cognitive data and volumetric MRI and PET results	No difference for APOE groups at baseline on any cognitive dimension. In the most recent report with the largest sample, memory decline over time was greater for the ϵ 4 group, especially on a verbal list learning test. Brain metabolic differences observed for APOE groups at baseline and over time
NIMH BIOCARD Study ^{18,162,163} Nondemented adults, 50–79 y. Most had first-degree relatives with AD	This group has reported baseline cognitive results and short-term (3 y) test-retest findings, focused primarily on experimental attention tasks and selected clinical memory tasks	ϵ 4 carriers, especially homozygotes, had reduced visuospatial attention, visual working memory, and delayed story recall at baseline, compared with noncarriers. Attentional scaling diverged longitudinally, with genotypes 2/4 and ϵ 4/4, but not 3/4, showing a decline in performance over time
WRAP ¹⁶ Through October, 2007, 820 middle-aged children of parents with AD and 305 controls whose parents were dementia-free have entered the study, and enrollment is continuing. AD in parents was identified by memory-clinic evaluation, autopsy, or record review	Only baseline data reported to date. In addition to cognitive testing, study procedures include blood and CSF assays, genetic analyses including APOE genotype, and fMRI. First 4-y retest began in 2006	No differences in baseline neuropsychologic performance for AD relatives vs. controls, or for ϵ 4 carriers vs. noncarriers. However, fMRI differences were observed in this sample as a function of family history
Washington University Adult Children Study ¹² Currently enrolling children of AD parents and controls with parents free of dementia. Presence of AD in the parent has been established through long-term longitudinal follow-up in the Memory and Aging Study and/or autopsy	In addition to cognitive testing, study procedures include PET with Pittsburgh Compound B, blood and CSF assays, genetic analyses including APOE genotype, structural MRI, and personality testing	No neuropsychologic results reported as yet
Framingham Offspring Study ¹⁷		

Sample	Design/Procedures	Results/Comments
Incident cases of AD have been identified within the original Framingham Heart Study cohort through long-term longitudinal follow-up. Children of the original cohort and their spouses comprise the Offspring Study, initiated in 1971. Between 1999 and 2003, 1400 offspring, including >200 with a parent who had AD, had brain MRI and neuropsychologic testing. There is also a comparison group of offspring whose parents remained free of dementia	Cognitive testing and brain MRI	No published neuropsychologic outcomes as yet

UCLA indicates University of California, Los Angeles; UCSD, University of California, San Diego.